SARS‐CoV‐2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Mossuto, Sandra; Attardi, Enrico; Alesiani, Francesco; Angelucci, Emanuele; Balleari, Enrico; Bernardi, Massimo; Binotto, Gianni; Bosi, Costanza; Calvisi, Anna; Capodanno, Isabella; Carbone, Antonella; Castelli, Andrea; Cerrano, Marco; Cilloni, Daniela; Clavio, Marino; Clissa, Cristina; Crisà, Elena; Crugnola, Monica; Porta, Matteo Giovanni Della; Renzo, Nicola Di; Fattizzo, Roberto; Fava, Carmen; Fenu, Susanna; Ferrara, Ida L; Fianchi, Luana; Filì, Carla; Finelli, Carlo; Giai, Valentina; Frattini, Francesco; Gaidano, Valentina; Guaragna, G.; Gumenyuk, Svitlana; Latagliata, Roberto; Mancini, Stefano; Messa, E.; Molteni, Alfredo; Musto, Pellegrino; Niscola, Pasquale; Olíva, Esther Natalie; Palumbo, Giuseppe A.; Pelizzari, Annamaria; Pilo, Federica; Poloni, Antonella; Riva, Marta Silvia Dalla; Rivellini, Flavia; Sarlo, Chiara; Sciumè, Mariarita; Secchi, Roberto; Selleri, Carmine; Tafuri, Agostino

doi:10.1097/hs9.0000000000000483

Cited by 10 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A greater proportion of patients with DLBCL (27/33, 81.8%) were on active CHOP-like chemotherapy when compared to patients with follicular lymphoma (22/54, 40.7%). Similarly, in a cohort of patients with myeloid dysplastic syndrome and COVID-19, the reported mortality rate was very high at almost 48% [ 49 ]. Most deceased patients (17/30) had high or very high IPSS-R prognostic scores, and as a result, the use of hypomethylating agents was overrepresented in the group of deceased patients (15/30) compared to those alive (5/33).…”

Section: The Impact Of Chemotherapy On Outcomesmentioning

confidence: 99%

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

et al. 2022

View full text Add to dashboard Cite

Patients with hematologic malignancies are particularly vulnerable to infections due to underlying humoral and cellular immune dysfunction, cytotoxic chemotherapy regimens, advanced age, and the presence of comorbid conditions. Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has become a leading cause of death globally and has disproportionally affected this high-risk population. Here, we review the cumulative evidence demonstrating worse outcomes for patients with hematologic malignancies when compared to patients with solid tumors and the general population. We examine risk factors shared with the general population (age, sex, comorbid conditions, race) and those that are cancer-specific (cytotoxic chemotherapy, progressive disease, cancer type), all of which confer an increased risk of severe COVID-19. Despite the historical exclusion of cancer patients from COVID-19 therapy trials, we review the emerging evidence that patients with hematologic malignancies benefit from specific treatments such as convalescent plasma. Although COVID-19 vaccines are significantly less effective in this patient population, encouraging results are observed in a subset of these patients after receiving a booster dose.

show abstract

Section: The Impact Of Chemotherapy On Outcomesmentioning

confidence: 99%

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Published data report a higher risk for Covid‐19 infections in patients with certain hematologic neoplasms as compared to the general population or patients with solid tumors 36–41 . Such diseases were acute leukemia, advanced MDSs, or lymphomas 22,27,39–41 . In contrast, other hematologic malignancies including myeloproliferative neoplasms might be a protective factor 42,43 .…”

Section: Discussionmentioning

confidence: 99%

“…Risk factors were active disease and treatment status 22 . In patients with myelodysplastic syndrome (MDS) a higher mortality rate from Covid‐19 infections compared to the general population was observed 27 . In Philadelphia‐negative myeloproliferative neoplasms, a mortality rate of 34% was found 25 .…”

Section: Introductionmentioning

confidence: 99%

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Graf

Herndlhofer

Kundi

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Background:The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. Materials and Methods: The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. Results: In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. Conclusions: Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.

show abstract

“…Epidemiology MDS, particularly in patients with high-risk disease, may pose an increased risk to severe COVID-19 and a risk or mortality similar to AML [8]. One report suggested a lethality rate of 73% among male MDS patients with COVID-19 [58]. Mortality was particularly high among patients in the higher risk categories.…”

Section: Myelodysplastic Syndromes (Mds)mentioning

confidence: 99%

The Care of the Leukemic Patients in Times of SARS-CoV-2

Karki

Cortés

2021

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe infection and increased rates of mortality. There is paucity of information on how to modify care of leukemia patients in view of the COVID-19 risks and imposed restrictions. We review the available literature on the impact of COVID-19 on different types of leukemia patients and suggest general as well as disease-specific recommendations on care based on available evidence. Recent Findings The COVID-19 infection impacts leukemia subtypes in variable ways and the standard treatments for leukemia have similarly, varying effects on the course of COVID-19 infection. Useful treatment strategies include deferring treatment when possible, use of less intensive regimens, outpatient targeted oral agents requiring minimal monitoring, and prioritization of curative or life-prolonging strategies. Reducing health care encounters, rational transfusion standards, just resource allocation, and pre-emptive advance care planning will serve the interests of leukemia patients. Summary Ad hoc modifications based on expert opinions and extrapolations of previous well-designed studies are the way forward to navigate the crisis. This should be supplanted with more rigorous prospective evidence.

show abstract

SARS‐CoV‐2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Cited by 10 publications

References 8 publications

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

The Care of the Leukemic Patients in Times of SARS-CoV-2

Contact Info

Product

Resources

About